LD 1178
pg. 2
Page 1 of 3 An Act Regarding Access to Prescription Drugs and Reimportation Page 3 of 3
Download Bill Text
LR 50
Item 1

 
D.__The program may provide access to prescription drugs that
are brand-name drugs and that are packaged in the original
sealed packaging.

 
E.__The program may not provide access to prescription drugs
that are controlled substances, that are sensitive to
environmental factors such as heat and cold or that are
antibiotics for acute illnesses.

 
3.__Advisory group.__The program must include an advisory
group made up of representatives of pharmacists, consumers and
licensed providers of health care authorized to prescribe in the
State, all of whom must be appointed by the commissioner.__The
advisory group must meet at least twice per year to review the
program, consider issues related to access, quality and safety
and advise the commissioner on program design and operation.__
Members of the advisory group serve as volunteers and are
entitled to reimbursement under Title 5, section 12004-I,
subsection 47-G.

 
4.__Testing.__The program must include a procedure for random
testing of drugs to ensure purity and safety for the patient.

 
5.__Rulemaking.__The department shall adopt rules to implement
this section, including rules governing member enrollment.__Rules
adopted pursuant to this subsection are routine technical rules
as defined in Title 5, chapter 375, subchapter 2-A.

 
SUMMARY

 
This bill establishes the Maine Save program to assist
consumers by providing access to drugs through Internet
connections to pharmacies and wholesale providers of prescription
drugs for residents who lack comprehensive prescription drug
coverage. The program provides access to brand-name drugs in
original sealed packaging. The program does not provide access
to drugs that are controlled substances, drugs that are sensitive
to environmental factors such as heat or cold or that are
antibiotics for acute illnesses. The program requires the patient
to show evidence of use of a pharmacist licensed in the State to
coordinate all prescriptions and prevent harmful drug
interactions. The program includes an advisory group to review
the program, consider issues related to access, quality and
safety and advise the Commissioner of Health and Human Services
regarding program design and operation. The program includes a
requirement for random testing of drugs. The bill includes


Page 1 of 3 Top of Page Page 3 of 3